August 26, 2024 – The U.S. Meals and Drug Administration has permitted and granted emergency authorization (EUA) for up to date mRNA COVID-19 vaccines (formulation 2024-2025) containing a monovalent (single) part similar to the Omicron variant KP.2 pressure of SARS-CoV-2. The mRNA COVID-19 vaccines have been up to date with this formulation to higher goal at present circulating variants and supply enhanced safety in opposition to extreme outcomes of COVID-19, together with hospitalization and demise. The FDA’s actions relate to up to date mRNA COVID-19 vaccines produced by ModernaTX Inc. and Pfizer Inc.

In early June, the FDA suggested producers of licensed and approved COVID-19 vaccines that the COVID-19 vaccines (System 2024-2025) needs to be monovalent JN.1 vaccines. Based mostly on the continued evolution of SARS-CoV-2 and a rise in COVID-19 instances, the company subsequently decided and suggested producers that the popular JN.1 lineage for the COVID-19 vaccines (System 2024-2025) is the KP.2 pressure, if possible.

Extra info